Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. amendment to a Schedule 13G/A reports that Jonathan Edward Hester beneficially owns 0 shares of Common Stock (CUSIP 007025869), representing 0% of the class. The filing lists the reporting person's address and certifies ownership is five percent or less.
Aditxt, Inc. reports an amended Schedule 13G filing by Andy Ni stating zero beneficial ownership in its Common Shares (CUSIP 007025869). The amendment lists 0 shares and 0% ownership and affirms the filer holds voting and dispositive power of 0 shares.
Aditxt, Inc. received notice that a Nasdaq Hearings Panel has denied its request to remain listed, and its common stock will be suspended from trading on Nasdaq at the open on June 25, 2026, pending delisting.
The decision follows prior findings that Aditxt violated the minimum $1.00 bid price requirement for 30 consecutive business days and reported stockholders’ equity of $(35,174,386) as of March 31, 2026, far below the $2,500,000 Nasdaq equity requirement. The Panel also cited seven reverse stock splits, continued losses of about $5 million per quarter, and skepticism about a proposed $150 million SPAC transaction for its Ignite Proteomics subsidiary as reasons not to grant an exception.
Aditxt, Inc. ownership disclosure: Emil Cristian Burciu reports beneficial ownership of 45,000 shares of Common Stock, equal to 5.5% of the class as of 06/16/2026. The filing lists sole voting and sole dispositive power over those 45,000 shares.
The filing gives the issuer address as 737 N. Fifth Street, Suite 200, Richmond, Virginia. The statement is signed and dated 06/23/2026 by Emil Cristian Burciu as an individual reporting person.
Aditxt, Inc. insider Tai Wey Ann filed an initial Form 3, reporting beneficial ownership of 100,000 shares of Aditxt common stock. The filing identifies Tai Wey Ann as a ten percent owner. This Form 3 is a disclosure of existing holdings and does not report any new buy or sell transactions.
Aditxt, Inc. shareholder Tai Wey Ann reports beneficial ownership of 100,000 shares of Common Stock, representing 12.3% of the class.
The filing lists sole voting and sole dispositive power over the 100,000 shares. The form is signed on 06/23/2026 and references 06/16/2026 on the cover.
Aditxt, Inc. expanded its senior secured convertible note financing to an aggregate original principal amount of $6,254,355.17 under an amended note purchase agreement with investors.
The company and its subsidiary Ignite Proteomics LLC issued an additional $769,230.77 in original principal amount of notes for a cash purchase price of $500,000.00, secured by substantially all Ignite assets and a pledge of Aditxt’s equity in Ignite.
The additional notes were sold as unregistered securities under Section 4(a)(2) and Rule 506(b) of Regulation D, and Aditxt had 997,976,543 common shares outstanding as of June 22, 2026.
Takeover Time 2026 LLC has filed an initial ownership report for Aditxt, Inc., stating a direct holding of Aditxt common stock. The filing shows that the entity is a ten percent owner and reports ownership of 3,420,439 shares of common stock following the reported position. This Form 3 is an initial statement of beneficial ownership and does not reflect a new purchase or sale but rather discloses an existing stake.
Takeover Time 2026 LLC filed a Schedule 13D reporting a significant equity position in Aditxt, Inc. (ADTX). The firm beneficially owns 3,420,439 shares of common stock, which it estimates to represent 10.9% of the class based on the best information currently available.
The reporting person states it acquired the shares on June 12, 2026 for investment purposes using its working capital, paying an aggregate purchase price of approximately $50,000, excluding commissions and other costs. It currently has no plans or proposals to change or influence control of Aditxt, but may buy or sell shares or engage with the company in the future depending on market conditions and other factors. Takeover Time 2026 LLC reports sole voting and dispositive power over all 3,420,439 shares and notes the actual ownership percentage may be higher, as the issuer’s most recently disclosed share count appears stale.
Aditxt, Inc. reports a Schedule 13G filing showing Jonathan Edward Hester beneficially owns 81,592 shares of Common Stock (06/15/2026), representing 9.9% of the class as reported. The filing notes the position equals approximately 9.9999% of outstanding shares and clarifies the 9.9% figure reflects EDGAR rounding.